Sera Prognostics, Inc.
NASDAQ:SERAMedical - Diagnostics & Research
-$0.03 today
- Market cap
- $74.11M
- Beta
- 0.94
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.64
Volume 0.01M
Average 0.06M
SERA Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Sera Prognostics, Inc.NASDAQ: SERA
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash declines year over year
Q1 FY2026 net change in cash of $231K fell 80.5% year over year, ahead of the -206.5% change in trailing-twelve-month net change in cash. Over 3 fiscal years it compounded at -85.0% a year.
Context
- Net change in cash amounted to 122.2% of revenue in FY2025, down 89.5 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -80.5% holds above the trailing-twelve-month pace of -206.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- (99K) USD
- Year-over-year change
- -160.7%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (99K) | -160.7% |
| FY2024 | 2024-12-31 | 163K | +100.6% |
| FY2023 | 2023-12-31 | (26M) | +10.5% |
| FY2022 | 2022-12-31 | (29.05M) | -164.0% |
| FY2021 | 2021-12-31 | 45.4M | — |
Net Change in Cash vs competitors
How SERA compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -206.5% is the lowest of 8, against a peer median of +47.7%.
- Net change in cash amounts to 1850.9% of revenue for SERA, versus a peer median of 51.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $14.8M USD | +181.1% | — | — | |
| LTM Mar 2026 | CA$7.58M CAD | -47.0% | -35.2% | — | |
| LTM Mar 2026 | $5.27M USD | -92.9% | — | 70.3% | |
| LTM Mar 2026 | $5.09M USD | +47.7% | — | 14.8% | |
| LTM Mar 2026 | $2.64M USD | +462.5% | — | 51.4% | |
| LTM Mar 2026 | $1.06M USD | -206.5% | -85.0% | 1850.9% | |
| LTM Mar 2026 | $336.9K USD | -96.9% | +51.6% | 84.9% | |
| LTM Mar 2026 | $126K USD | +102.0% | -96.4% | 0.2% | |
| LTM Mar 2026 | $78.3K USD | — | — | — | |
| Peer median (excluding SERA) | — | +47.7% | -35.2% | 51.4% | |
Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (35.01M) | (44.19M) | (36.24M) | (32.9M) | (31.93M) |
| Depreciation & Amortization | 659K | 756K | 900K | 833K | 940K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.13M | 5.06M | 5.27M | 7.01M | 5.11M |
| Change in Working Capital | (44K) | 3.55M | 3.52M | 11.28M | (546K) |
| Accounts Receivables | (3.14M) | (2.97M) | (5.36M) | 11.42M | 22K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 603K | 352K | (442K) | 455K | (1.01M) |
| Other Working Capital | 2.49M | 6.17M | 9.32M | (597K) | 441K |
| Other Non-Cash Items | (372K) | 213K | (638K) | (412K) | 801K |
| Operating Cash Flow | (31.64M) | (34.61M) | (27.19M) | (14.19M) | (25.62M) |
| Capital Expenditures | (1.3M) | (791K) | (128K) | (1.1M) | (726K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (82.06M) | (48.07M) | (54.14M) | (35.83M) | (87.61M) |
| Sales of Investments | 800K | 54.4M | 54.4M | 48.68M | 59.84M |
| Other Investing Activities | 0 | 16K | 311K | (1.05M) | 0 |
| Investing Cash Flow | (82.56M) | 5.55M | 438K | 11.74M | (28.5M) |
| Debt Repayment | (7.66M) | (303K) | (466K) | (440K) | (194K) |
| Common Stock Issued | 66.61M | 0 | 0 | 0 | 54.22M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.66M | 308K | 1.22M | 3.05M | 0 |
| Financing Cash Flow | 159.59M | 5K | 752K | 2.61M | 54.03M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 45.4M | (29.05M) | (26M) | 163K | (99K) |
| Free Cash Flow | (32.94M) | (35.4M) | (27.32M) | (15.29M) | (26.35M) |
Sera Prognostics, Inc.
NASDAQ:SERA
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.